|[April 17, 2014]
Research and Markets: GSK's Fendrix (Prophylactic Hepatitis B Virus Vaccines) Market 2014- Forecast Opportunities to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/ch937q/fendrix)
has announced the addition of the "Fendrix
(Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis
to 2022" report to their offering.
Fendrix [Hepatitis B (rDNA) Vaccine (adjuvanted, adsorbed)] is GSK's
monovalent vaccine that protects patients against acute and chronic
infections caused by all identified strains of HBV. Since 2005, Fendrix
has been approved in the 5EU for the active immunization of patients =15
years of age with renal insufficiency (i.e., pre-hemodialsis and
- Overview of Hepatitis B disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Detailed information on Fendrix including product description, safety
and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fendrix for top eight countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain,
UK, Japan and Canada.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.2 Etiology and Pathophysiology
3.4 Prognosis (News - Alert)
4 Vaccination Recommendations and Coverage Rates
5 Competitive Assessment
5.2 Strategic Competitor Assessment
6.4 SWOT Analysis
For more information visit http://www.researchandmarkets.com/research/ch937q/fendrix
[ InfoTech Spotlight's Homepage ]